reactivation using real-time PCR (Quiagen Artus EBV RG PCR ASR, Hamburg, Germany) and use of rituximab was assessed considering the inherent risk of developing post-transplant lymphoproliferative disorder (PTLD). CMV reactivation was assessed by PCR (Quiagen Artus). TAC started on day − 3 at 0.01 mg/kg (ideal body weight), initially as IV and later converted to oral formulation. Starting dose of SIR was 12 mg (day − 1) followed by 4 mg/day starting on day 0. The goal level range for TAC was 3-7 ng/mL and for SIR was 8-14 ng/mL. All received ATG (rabbit thymoglobulin, Sanofi, Paris, France) at a total dose of 7.5 mg/kg: 1 mg/kg (day − 3) followed by 3.25 mg/kg/day (days − 2 and − 1). EBV was monitored weekly from day 0 until day +100. Based on our practice, a titer exceeding 1000 copies/mL prompted initiation of rituximab 375 mg/m 2 . Persistent EBV viremia, where quantitative PCR showed less than a one-log reduction, would have prompted three additional weekly rituximab doses. For CMV, we followed a preemptive treatment approach where anti-CMV therapy was initiated if CMV copies exceeded 1000/ml or at lower levels if clinically indicated.
Baseline characteristics were summarized using descriptive statistics including mean, median, s.d. and range for continuous measures and frequencies and proportion for categorical measures. Probabilities for RFS and OS were calculated using the Kaplan-Meier estimate. Cumulative incidence of NRM and relapse were evaluated using a competing-risks model by Gray, 11 with relapse and death as competing factors, respectively. Similarly, cumulative incidences of grade II-IV aGVHD and cGVHD were estimated accounting for death and relapse as competing events. Neutrophil engraftment was defined as the first of 3 consecutive days of an ANC ⩾ 500/μL. Platelet engraftment was defined as the first of 7 days without platelet transfusion. Also, aGVHD and cGVHD were graded using 1996 consensus criteria 12 and National Institute of Health (NIH) consensus. 13 Sinusoidal obstructive syndrome (SOS) and thrombotic microangiopathy (TMA) were diagnosed based on criteria by the Blood and Marrow Transplant Clinical Trial Network 14 and McDonald et al., 15 respectively. Median age was 56 (24-67) years. The majority were allografted for a myeloid malignancy (63%) using a myeloablative regimen (74%). Median number of infused CD34+ cells (×10 6 /recipient weight in kg) was 8.6 (3.2-23.0). These and other characteristics are summarized in Table 1 .
Median follow-up from the day of cell infusion (day 0) for all surviving patients was 13.04 (2.92-55.0) months. There were no primary graft failures. Median time-to-ANC and platelet engraftment were 14 (12-24) days and 15 (10-27) days, respectively. One patient's platelets never dropped o20 000/μL. The 100-day incidence of grade II-IV aGVHD was 56% (95% confidence interval (CI) = 35-72%); and for grade III-IV aGVHD was 11% (95% CI = 3-26%). Incidence of cGVHD (NIH-moderate and severe) was 23% (95% CI = 9%-41%). Two-year NRM was 16% (95% CI = 5-33%) ( Figure 1a ). There were only 4 non-relapse deaths owing to GVHD (n = 1), viral infection (n = 2) and unknown (n = 2). Two-year cumulative incidence of relapse was 28% (95% CI = 12-46%) (Figure 1a) . Two-year RFS and OS ( Figure 1b) were 57% (95% CI = 36-73%) and 80% (95% CI = 58-91%), respectively. At 1-year follow-up, only 2 (10%) of 20 evaluable patients were off immune suppression. Two (7%) patients developed SOS on days +35 and +68, and 2 (7%) other developed TMA on days +43 and +70, respectively. None of the non-relapse deaths were attributable to SOS or TMA. Preemptive rituximab was prescribed in 78% but none developed PTLD. Median time-to-first EBV reactivation was 26 (18-100) days. Within the first 100 days, 8 (30%) developed CMV reactivation, at a median of 34 (16-91) days, requiring therapy. All eight patients were CMV seropositive preallografting.
TAC-SIR-ATG is a feasible GVHD prophylaxis regimen for MMUD allo-HCT. An encouraging OS occurred despite a relatively older population (median age of 56 years) and over half of them (56%) having intermediate-or high-risk disease by CIBMTR criteria. Older age is known to result in inferior survival after allo-HCT. Moreover, this encouraging OS is explained in part by the relatively low 2-year NRM of 16%.
Administration of TAC-SIR-ATG as GVHD prophylaxis resulted in high incidence of EBV reactivation, requiring rituximab administration. Our incidence of EBV reactivation (78%) was certainly higher than reported by Al-Kadhimi et al.
9 (20%). One explanation is the higher (67%) cumulative dose of ATG used at our center (7.5 vs 4.5 mg/kg). None of the patients who reactivated EBV developed or died from PTLD.
Cumulative incidence of grade II-IV aGVHD in our study was 56% (95% CI = 35-72%), certainly higher than the 23.4% grade II-IV incidence of aGVHD reported by others. 9 However, all of our patients received MMUD grafts (19% had two mismatches; Table 1 ), whereas in the study by Al-Kadhimi et al.
9 47% were allografted from MRDs, who are inherently at lower risk of developing aGVHD. This is also the case for Khaled et al. 10 who reported a cumulative incidence of aGVHD of 37.3%; but 56% of enrolled patients were allografted from a HLA MUDs. With regards to cGVHD, our study compared favorably to Khaled et al. 10 who reported extensive cGVHD in 17 (68%) of 25 evaluable patients. One notable difference among the studies was the ATG dose. In our study, a total of 7.5 mg/kg was prescribed, whereas the total ATG dose in Khaled et al. 10 and Al-Khadimi et al. 9 were only 4.5 mg/kg, respectively. In Al-Kadhimi et al., 9 the cumulative incidence of cGVHD (all grades) was 33% (mild = 8/16, moderate/ severe = 8/16).
Use of TAC-SIR-ATG resulted in timely ANC and platelets engraftment and we did not observe graft failure. Our study shows a 7% incidence of SOS and 7% incidence of TMA with TAC-SIR-ATG. One patient who developed SOS died from relapsed AML and another is alive after 30+ months. Moreover, two patients who developed TMA are alive at 26 and 35 months post-transplantation. Given the potential morbidity and mortality from SOS or TMA, transplant team members must be familiar with best practice management of these complications. We acknowledge several limitations, including the study's retrospective nature and the relatively small sample size. Although it is arguable that our analysis has a relatively short follow-up, one should note that negative post-transplant outcomes, notably NRM, commonly occur in the first year post-transplantation. In our program, SIR has become the preferred agent for GVHD prophylaxis in comparison to methotrexate or mycophenolate mofetil 7 and adding ATG was the reasonable approach towards improving GVHD control in MMUD allo-HCT. Notwithstanding these limitations, the encouraging OS seen with TAC-SIR-ATG in MMUD is intriguing and requires confirmation. Optimal ATG dose is another important question that remains unanswered.
